Plain-English translation of NCT07134335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a medication called , given as a weekly injection, to see if it can help people with chronic kidney disease who are also overweight or obese. Researchers want to learn whether this medication is safe and effective, and what dose works best. About 180 people will participate across multiple medical centers.
People with chronic kidney disease who struggle with their weight face serious health challenges, and there are limited treatment options specifically designed for them. This study is exploring whether this medication could help protect kidney function while also supporting weight management.
You likely qualify if…
You likely don't qualify if…
If you are accepted into the study, you will receive weekly injections under your skin for 24 weeks. The dose will start low and gradually increase over the first 13 weeks, then stay steady. You will be randomly assigned to receive one of three different dose levels or a placebo (a dummy injection with no medication). You'll need to attend multiple study visits for blood tests, urine tests, and check-ins with the research team to monitor your kidney function, weight, and overall health.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The United Bio-Technology (Hengqin) Co., Ltd.
Enrollment target
~180 participants
Started
September 2025
Primary completion
July 2030
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wen Bian
The United Bio-Technology (Hengqin) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.